Neuroscience
From FierceBiotech:
FDA approves Acorda's new MS drug
January 22, 2010 — 4:49pm ET
By John Carroll
[snip]
The FDA announced Friday afternoon that it has approved Ampyra (dalfampridine) extended-release tablets to improve walking in patients with multiple sclerosis. In clinical trials, patients treated with Ampyra had faster walking speeds than those treated with a placebo. This is the first drug approved for this use.
[snip]
Read the FierceBiotech full article
- Fda: Progressive Multifocal Leukoencephalopathy (pml) And Tysabri (natalizumab)
From the FDA: FDA permits marketing of first test for risk of rare brain infection in some people treated with Tysabri For Immediate Release: January 20, 2012 [snip]"Today, the U.S. Food and Drug Administration allowed marketing of the first test to...
- Merck's Cladribine And Multiple Sclerosis
From FierceBiotech: Merck KGaA pulls ahead in hot oral MS drug race By John Carroll September 11, 2009 — 8:22am ET Researchers for Merck KGaA say that new analysis of the late-stage data for their oral drug cladribine highlight the drug's potential...
- Rasagiline And Parkinson's Disease
From the FDA on the 17th of May: FDA Approves New Treatment for Parkinson's Disease The Food and Drug Administration today approved Azilect (rasagiline), a new molecular entity, for the treatment of Parkinson's disease. The drug is a monoamine...
- Post Tysabri (natalizumab): What Choices In M.s. Treatment?
The Consumer: Exploring Choices for M.S. By MARY DUENWALD The New York Times 15 March 2005 [snip] An estimated 5,000 patients who had been taking Tysabri since the Food and Drug Administration approved it in late November are now advised to see their...
- Cymbalta And Diabetic Peripheral Neuropathy
The Food and Drug Administration (FDA) today announced its approval of this medication as a treatment for a common neurological complication of diabetes. From the press release: FDA Approves Drug for Neuropathic Pain Associated With Diabetes Today...
Neuroscience
FDA Approves Multiple Sclerosis Drug, Ampyra (dalfampridine) Extended-release
From FierceBiotech:
FDA approves Acorda's new MS drug
January 22, 2010 — 4:49pm ET
By John Carroll
[snip]
The FDA announced Friday afternoon that it has approved Ampyra (dalfampridine) extended-release tablets to improve walking in patients with multiple sclerosis. In clinical trials, patients treated with Ampyra had faster walking speeds than those treated with a placebo. This is the first drug approved for this use.
[snip]
Read the FierceBiotech full article
- Fda: Progressive Multifocal Leukoencephalopathy (pml) And Tysabri (natalizumab)
From the FDA: FDA permits marketing of first test for risk of rare brain infection in some people treated with Tysabri For Immediate Release: January 20, 2012 [snip]"Today, the U.S. Food and Drug Administration allowed marketing of the first test to...
- Merck's Cladribine And Multiple Sclerosis
From FierceBiotech: Merck KGaA pulls ahead in hot oral MS drug race By John Carroll September 11, 2009 — 8:22am ET Researchers for Merck KGaA say that new analysis of the late-stage data for their oral drug cladribine highlight the drug's potential...
- Rasagiline And Parkinson's Disease
From the FDA on the 17th of May: FDA Approves New Treatment for Parkinson's Disease The Food and Drug Administration today approved Azilect (rasagiline), a new molecular entity, for the treatment of Parkinson's disease. The drug is a monoamine...
- Post Tysabri (natalizumab): What Choices In M.s. Treatment?
The Consumer: Exploring Choices for M.S. By MARY DUENWALD The New York Times 15 March 2005 [snip] An estimated 5,000 patients who had been taking Tysabri since the Food and Drug Administration approved it in late November are now advised to see their...
- Cymbalta And Diabetic Peripheral Neuropathy
The Food and Drug Administration (FDA) today announced its approval of this medication as a treatment for a common neurological complication of diabetes. From the press release: FDA Approves Drug for Neuropathic Pain Associated With Diabetes Today...